ACLX
Price
$58.27
Change
-$1.22 (-2.05%)
Updated
May 13, 04:59 PM (EDT)
Capitalization
3.21B
96 days until earnings call
SGMO
Price
$0.46
Change
-$0.29 (-38.67%)
Updated
May 13, 04:59 PM (EDT)
Capitalization
105.43M
90 days until earnings call
Ad is loading...

ACLX vs SGMO

Header iconACLX vs SGMO Comparison
Open Charts ACLX vs SGMOBanner chart's image
Arcellx
Price$58.27
Change-$1.22 (-2.05%)
Volume$17.82K
Capitalization3.21B
Sangamo Therapeutics
Price$0.46
Change-$0.29 (-38.67%)
Volume$44.26K
Capitalization105.43M
ACLX vs SGMO Comparison Chart
Loading...
ACLX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SGMO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ACLX vs. SGMO commentary
May 14, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACLX is a Hold and SGMO is a Hold.

Ad is loading...
COMPARISON
Comparison
May 14, 2025
Stock price -- (ACLX: $59.50 vs. SGMO: $0.75)
Brand notoriety: ACLX and SGMO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ACLX: 86% vs. SGMO: 101%
Market capitalization -- ACLX: $3.28B vs. SGMO: $171.16M
ACLX [@Biotechnology] is valued at $3.28B. SGMO’s [@Biotechnology] market capitalization is $171.16M. The market cap for tickers in the [@Biotechnology] industry ranges from $296.96B to $0. The average market capitalization across the [@Biotechnology] industry is $2.15B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ACLX’s FA Score shows that 0 FA rating(s) are green whileSGMO’s FA Score has 0 green FA rating(s).

  • ACLX’s FA Score: 0 green, 5 red.
  • SGMO’s FA Score: 0 green, 5 red.
According to our system of comparison, both ACLX and SGMO are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ACLX’s TA Score shows that 4 TA indicator(s) are bullish while SGMO’s TA Score has 4 bullish TA indicator(s).

  • ACLX’s TA Score: 4 bullish, 6 bearish.
  • SGMO’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, SGMO is a better buy in the short-term than ACLX.

Price Growth

ACLX (@Biotechnology) experienced а -7.97% price change this week, while SGMO (@Biotechnology) price change was +3.72% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.49%. For the same industry, the average monthly price growth was +10.87%, and the average quarterly price growth was -7.60%.

Reported Earning Dates

ACLX is expected to report earnings on Aug 18, 2025.

SGMO is expected to report earnings on Aug 12, 2025.

Industries' Descriptions

@Biotechnology (+1.49% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ACLX($3.21B) has a higher market cap than SGMO($105M). ACLX YTD gains are higher at: -22.415 vs. SGMO (-26.784). SGMO has higher annual earnings (EBITDA): -89.09M vs. ACLX (-99.06M). ACLX has more cash in the bank: 587M vs. SGMO (41.9M). SGMO has less debt than ACLX: SGMO (30.6M) vs ACLX (54.1M). ACLX has higher revenues than SGMO: ACLX (108M) vs SGMO (57.8M).
ACLXSGMOACLX / SGMO
Capitalization3.21B105M3,057%
EBITDA-99.06M-89.09M111%
Gain YTD-22.415-26.78484%
P/E RatioN/AN/A-
Revenue108M57.8M187%
Total Cash587M41.9M1,401%
Total Debt54.1M30.6M177%
FUNDAMENTALS RATINGS
SGMO: Fundamental Ratings
SGMO
OUTLOOK RATING
1..100
60
VALUATION
overvalued / fair valued / undervalued
1..100
62
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
99
PRICE GROWTH RATING
1..100
64
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ACLXSGMO
RSI
ODDS (%)
Bullish Trend 2 days ago
88%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
89%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bearish Trend 2 days ago
74%
Bullish Trend 2 days ago
83%
MACD
ODDS (%)
Bearish Trend 2 days ago
76%
Bullish Trend 2 days ago
72%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
78%
Bullish Trend 2 days ago
77%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
88%
Bullish Trend 2 days ago
78%
Advances
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 6 days ago
74%
Declines
ODDS (%)
Bearish Trend 8 days ago
79%
Bearish Trend 8 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
80%
Aroon
ODDS (%)
Bearish Trend 2 days ago
69%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Ad is loading...
ACLX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SGMO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
TSLA318.3820.12
+6.75%
Tesla
AAPL210.7912.52
+6.31%
Apple
SPY582.9918.65
+3.30%
SPDR® S&P 500® ETF
GME28.050.51
+1.85%
GameStop Corp
BTC.X102812.950000-1293.406200
-1.24%
Bitcoin cryptocurrency

ACLX and

Correlation & Price change

A.I.dvisor indicates that over the last year, ACLX has been loosely correlated with KRYS. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if ACLX jumps, then KRYS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ACLX
1D Price
Change %
ACLX100%
+3.39%
KRYS - ACLX
58%
Loosely correlated
+5.48%
RCKT - ACLX
58%
Loosely correlated
+0.14%
XNCR - ACLX
57%
Loosely correlated
+5.28%
CGON - ACLX
56%
Loosely correlated
+5.98%
DNLI - ACLX
55%
Loosely correlated
+2.99%
More

SGMO and

Correlation & Price change

A.I.dvisor indicates that over the last year, SGMO has been loosely correlated with XNCR. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if SGMO jumps, then XNCR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SGMO
1D Price
Change %
SGMO100%
+6.66%
XNCR - SGMO
36%
Loosely correlated
+5.28%
ANIX - SGMO
31%
Poorly correlated
+1.92%
ACLX - SGMO
29%
Poorly correlated
+3.39%
BEAM - SGMO
29%
Poorly correlated
+4.77%
RPTX - SGMO
29%
Poorly correlated
N/A
More